Free press releases distribution network?

Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Novozymes Biopharma Collaborates with the University of Oslo to Develop Albumin Fusion Technology - Albufuse Flex next-generation technology has been developed to tailor and control the pharmacokinetics of target proteins and peptides for flexible, optimal use
Novozymes Biopharma Collaborates with the University of Oslo to Develop Albumin Fusion Technology

 

PRZOOM - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2011/05/06 - Albufuse Flex next-generation technology has been developed to tailor and control the pharmacokinetics of target proteins and peptides for flexible, optimal use.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Novozymes Biopharma, part of Novozymes A/S, the world leader in bioinnovation, today unveiled its enhanced next-generation albumin technology, which was developed in collaboration with the University of Oslo, Norway, one of the world’s leading institutions in the research of albumin variants and the neonatal Fc receptor (FcRn).
Built on Novozymes’ original Albufuse platform, the proprietary Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.

“Novozymes Biopharma is thrilled to introduce Albufuse Flex to the industry,” says Dave Mead, Business Development Director at Novozymes Biopharma. “Albumin is a natural and benign carrier molecule, and by having the unique ability to decrease or increase its half-life it will help our customers to develop novel drugs with improved pharmacokinetic properties for a wide range of applications.”

It has been shown that by manipulating the interaction of albumin and IgGs with FcRn it is possible to tailor their half-life. The Albufuse Flex technology has been developed to facilitate manipulation based on this FcRn–albumin interaction, enabling a tunable half-life that offers control and flexibility and that, potentially, may improve overall treatment efficacy and patient compliance. In addition to protein- or peptide-based drugs, the enhanced technology also provides a delivery vehicle for small molecules, providing a broad scope of usability.

The enhanced half-life technology has been developed by Novozymes in collaboration with scientists at the University of Oslo. The innovative research developed by the university into the interaction between albumin variants and the neonatal Fc receptor (FcRn) was fundamental in the development of Albufuse Flex.

Professor Inger Sandlie, Group leader at the Norwegian Centre of Excellence for Immune Regulation, says: “The efficacy of peptides, small proteins, and engineered antibody fragments is hampered by short serum half-life.
Therefore, strategies to tailor their serum persistence and biodistribution are needed. The unique Albufuse Flex technology solves this problem and will result in enhanced treatment efficacy, more favorable dosing regimes, and improved patient compliance.”

“The successful development of the Albufuse Flex technology illustrates the importance of industry and academic collaboration in turning scientific excellence into products that address medical needs. Novozymes has been an outstanding partner throughout the development process, and the company truly understands the potential of our academic science,” says Dr Jørund Sollid, Inven2 AS, the university technology transfer office.

• Albufuse Flex is a registered trademark of albumin fusion technology.

For further information on Novozymes’ new Albufuse Flex technology, please visit biopharma.novozymes.com/.

About Novozymes
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow’s industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace. Read more at novozymes.com.

About Inven2 – Oslo Technology Transfer
Inven2 (inven2.com) is the technology transfer office of the University of Oslo, Norway’s largest institution of higher education, Oslo University Hospital, and all hospitals in the south-eastern region of Norway. Its mission it to turn excellent science into products, mainly in the field of life sciences.

The University of Oslo, together with the hospitals, discloses around 200 unique inventions annually. This results in an annual activity of 60+ new patent filings, 20+ license agreements, and 4–8 start-up companies. As of today, Inven2 has a portfolio of 22 technology start-ups and a range of licensing agreements, with the discovery of the biomarker NT-proBNP as the biggest commercial success at present.

Contact:
Novozymes Biopharma:
Sally Vernon, Customer Communications Manager SYKE[.]novozymes.com T: +44 115 955 3355

MEDIA CONTACTS
Europe, René Tronborg
Office: +45 4446 2274 / Mobile: +45 3077 2274 - E: retr[.]novozymes.com.

US, Paige Donnelly
Office: +1 919 494 3209 / Mobile: +1 919 218 4501 - E: pagd[.]novozymes.com.

China, Zhu Xiaoqing
Office: +86 106 298 7888+362 / Mobile: +86 138 012 40590 - E: xqzh[.]novozymes.com.

Brazil, Saionara Ribeiro de Paula
Office: +55 41 3641 1112 / Mobile: +55 41 9971 7225 - E: saio[.]novozymes.com.

INVESTOR CONTACTS
Europe, Tobias Bjorklund
Office: +45 4446 8682 / Mobile: +45 3077 8682 - E: tobb[.]novozymes.com.

US, Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565 / E: tsbm[.]novozymes.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma Collaborates with the University of Oslo to Develop Albumin Fusion Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Scottpr.com 
+44 1477 539539 novozymes[.]scottpr.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From The Scott Partnership / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Medical Tapes Market to Reach US$ 2Bn by 2024 Reports PMR
Global Pyrogen Testing Market Value Expected to Increase to US$ 1.37 Billion by 2024 Says PMR
Huber Needles Market Expected to Reach US$ 55M by 2024 According to PMR
ZOLL Technologies for Improving CPR Quality to be Showcased at NTI 2017
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men
Biomarker-based Technologies to Disrupt Conventional Diagnosis in Diabetes Management across the Globe Finds Frost & Sullivan
Agfa Specialty Products Announces the Launch of UNIQOAT
Sparta Releases Stratas 3.0 and TrackWise Intake
GE Healthcare Signs Agreement with HealthTrust to Supply Radiopharmaceuticals
GE Introduces CardioGraphe - The World’s First Dedicated Cardiovascular CT System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Persistence Market Research (P) Ltd

Visit  MagLar, Inc.

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today